Skip to main content

Fosun Forms JV with BioNTech to Manufacture COVID-19 Vaccine

Shanghai Fosun Pharma will form a JV with its German partner BioNTech to manufacture COVID-19 vaccine in China. In March, Fosun acquired China rights to BioNTech's mRNA vaccine in a $135 million deal that included a $50 million Fosun investment in BioNTech. Under the agreement, Fosun agreed to purchase 100 million doses of the vaccine for China use. Now, the JV will follow that up by initially purchasing bulk ingredients from BioNTech to fill and finish, and then making vaccines itself in a facility with a 200 million dose capacity. More details.... Stock Symbols: (SHA: 600196; HK: 02196) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.